Skip to main content
. 2001 Apr;39(4):1247–1253. doi: 10.1128/JCM.39.4.1247-1253.2001

FIG. 2.

FIG. 2

WB analysis using WB2.4 from Genelabs Diagnostic Biotechnology. Lane 1, HTLV-1-positive control; lane 2, HTLV-2-positive control; lane 3, serum from one Guadeloupean blood donor with an isolated p24 band; lanes 4 and 5, sera from two Guadeloupean blood donors with an HGIP; lane 6, serum from one Guadeloupean blood donor exhibiting gd21 (weak), p19, p26, p28, p32, p36, and pr53 bands but without reactivities to both p24 and env-encoded glycoprotein MTA-1; lanes 7 and 8, sera from three Guadeloupean blood donors exhibiting gd21, p19, p26, p28, p32, p36, and pr53 bands but without reactivities to both p24 and MTA-1; lane 9, serum from one Guadeloupean blood donor exhibiting reactivities to gd21, p24, and p28, but without reactivities to both p19 and MTA-1; lane 10, serum from one Guadeloupean blood donor with a nearly complete WB profile but lacking p24 reactivity. This subject was positive in PCR.